European Commission Finally Delivers On GMP Standards For ATMPs
Executive Summary
Following protracted consultations with stakeholders on how best to specify good manufacturing practice standards for advanced therapies, the European Commission has at last published the long-awaited guideline. The industry is now keen to work with EU inspectors and competent authorities to develop a common understanding of the risk-based principles outlined in the final document.
You may also be interested in...
The EMA Explains How To Obtain Exemptions From Advanced Therapy Import Testing Requirements
Manufacturers of advanced therapy medical products were given guidance on what data they need to submit to the EMA to support their requests to have drugs exempted from import testing requirements.
EMA Explains When 'Out Of Specification' CAR-Ts Can Be Given To Patients
The European Medicines Agency must be informed about each 'out of specification' batch of a cell or tissue-based advanced therapy that has been granted marketing authorization. The agency warns that if a trend is discovered, it may consider the need for regulatory actions.
Quality Expert Urges Firms To Adopt QbD Approach When Developing Cell Therapies
Expert explains how firms can leverage pharmaceutical quality-by-design principles when developing cell therapies to help make sure their manufacturing processes remain in a state of control over the product lifecycle.